Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Assets Measured at Fair Value on Recurring Basis

The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

June 30, 2021	Level 1		Level 2		Level 3		Total
Assets
Money market securities (cash equivalents)		41,289		—		—		41,289
Restricted cash		50		—		—		50
Total assets	$	41,339	$	—	$	—	$	41,339

Summary of Cash Equivalents

Cash equivalents consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
June 30, 2021	Cost		Gains		Losses		Fair Value
Money market securities	$	41,289	$	—	$	—	$	41,289
Total cash equivalents	$	41,289	$	—	$	—	$	41,289
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50